Clinical trial
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic…
NCT00496860 · Altor BioScience, Industry · Completed
Key facts
| NCT number | NCT00496860 |
|---|---|
| Title | Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies |
| Official title | Phase I Study of ALT-801 in Patients With Progressive Metastatic Malignancies |
| Lead sponsor | Altor BioScience, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Progressive Metastatic Malignancies |
| Intervention type | Biological |
| Interventions | ALT-801 |
| Enrollment | 26 |
| Start date | May 1, 2007 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Jul 4, 2007 |
| Last update posted | Jul 22, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: